retatrutide nonalcoholic fatty liver disease nash trial Retatrutide Significantly Reduces Visceral Fat in Clinical Trials retatrutide nash trial nonalcoholic fatty

Sources FDA drug shortage: Food & Drug Administration (no date)

This type of pattern makes a potential link more compelling than a single, static finding and provides a significant signal that warrants serious follow-up investigation. However, Vavvas did point out that the study has some limitations

According to clinical trials, gastrointestinal symptoms typically peak during the first 48 weeks of therapy, with substantial improvement for many patients by 1216 weeks, though individual experiences vary based on the specific medication and titration schedule

Presented for research literature review only Evelo CT et al